Protein corona–mediated targeting of nanocarriers to B cells allows redirection of allergic immune responses

Shen, Limei; Tenzer, Stefan; Storck, Wiebke; Hobernik, Dominika; Raker, Verena; Fischer, Karl; Decker, Sandra; Dzionek, Andrzej; Krauthäuser, Susanne; Diken, Mustafa; Nikolaev, Alexej; Maxeiner, Joachim; Schuster, Petra; Kappel, Cinja; Verschoor, Admar; Schild, Hansjörg; Grabbe, Stephan; Bros, Matthias

doi:10.1016/j.jaci.2017.08.049

Cited by 65 publications

(56 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…17) Therefore, the spleen is a good candidate for gene therapy for the treatment of immune-related diseases including allergies, inflammations, infections, and cancer. 20,[92][93][94] The most critical point is to target specific types of spleen cells for achieving a level of gene delivery sufficient for producing a therapeutic effect. This section focuses on in vivo spleen-targeted gene delivery using lipid-based nanocarriers focusing mainly on delivering genes to specific spleen cells.…”

Section: Lnps For Gene Delivery To Spleen Cellsmentioning

confidence: 99%

“…117) Colluru et al showed that murine B cells, but not DCs, co-cultured with pDNA efficiently express the antigen and elicit antigen-specific T cell activity in vivo. 118) Shen et al reported that dextran NPs targeted B cells in the spleen through complement activation and produced strong antigen-specific activation. 119) These NPs were used for preventing the induction of anaphylactic shock and allergic asthma.…”

Section: Applications For Spleen Gene Deliverymentioning

confidence: 99%

See 1 more Smart Citation

Lipid Nanoparticles for Cell-Specific <i>in Vivo</i> Targeted Delivery of Nucleic Acids

Khalil

Younis

Kimura

et al. 2020

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

The last few years have witnessed a great advance in the development of nonviral systems for in vivo targeted delivery of nucleic acids. Lipid nanoparticles (LNPs) are the most promising carriers for producing clinically approved products in the future. Compared with other systems used for nonviral gene delivery, LNPs provide several advantages including higher stability, low toxicity, and greater efficiency. Additionally, systems based on LNPs can be modified with ligands and devices for controlled biodistribution and internalization into specific cells. Efforts are ongoing to improve the efficiency of lipid-based gene vectors. These efforts depend on the appropriate design of nanocarriers as well as the development of new lipids with improved gene delivery ability. Several ionizable lipids have recently been developed and have shown dramatically improved efficiency. However, enhancing the ability of nanocarriers to target specific cells in the body remains the most difficult challenge. Systemically administered LNPs can access organs in which the capillaries are characterized by the presence of fenestrations, such as the liver and spleen. The liver has received the most attention to date, although targeted delivery to the spleen has recently emerged as a promising tool for modulating the immune system. In this review, we discuss recent advances in the use of LNPs for cellspecific targeted delivery of nucleic acids. We focus mainly on targeting liver hepatocytes and spleen immune cells as excellent targets for gene therapy. We also discuss the potential of endothelial cells as an alternate approach for targeting organs with a continuous endothelium.

show abstract

Section: Lnps For Gene Delivery To Spleen Cellsmentioning

confidence: 99%

Section: Applications For Spleen Gene Deliverymentioning

confidence: 99%

Lipid Nanoparticles for Cell-Specific <i>in Vivo</i> Targeted Delivery of Nucleic Acids

Khalil

Younis

Kimura

et al. 2020

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

show abstract

“…The adsorption happens immediately when nanoparticles enter the blood stream and has been termed 'biomolecular or protein corona formation'. [8][9][10] Specific proteins such as immunoglobulins 11 and complement proteins 12 are known to mediate interactions with phagocytic cells and hereby influence the clearance process ('opsonization'). 13,14 There are different reports, which could prove a direct recognition of corona proteins by specific cell-receptors.…”

Section: Introductionmentioning

confidence: 99%

Exploiting the biomolecular corona: pre-coating of nanoparticles enables controlled cellular interactions

et al. 2018

View full text Add to dashboard Cite

Formation of the biomolecular corona ultimately determines the successful application of nanoparticles in vivo. Adsorption of biomolecules such as proteins is an inevitable process that takes place instantaneously upon contact with physiological fluid (e.g. blood). Therefore, strategies are needed to control this process in order to improve the properties of the nanoparticles and to allow targeted drug delivery. Here, we show that the design of the protein corona by a pre-formed protein corona with tailored properties enables targeted cellular interactions. Nanoparticles were pre-coated with immunoglobulin depleted plasma to create and design a protein corona that reduces cellular uptake by immune cells. It was proven that a pre-formed protein corona remains stable even after nanoparticles were re-introduced to plasma. This opens up the great potential to exploit protein corona formation, which will significantly influence the development of novel nanomaterials.

show abstract

“…The “protein corona” around NC may affect their organ-specific or cell type-specific trafficking as well as endocytosis and/or functional properties of the NC ( 10 ). Most importantly, the protein corona has been shown to interfere with targeting moieties used to induce receptor-mediated uptake of the NC, both inhibiting ( 11 ) and enhancing ( 12 ) internalization by specific cell types. Moreover, the protein corona is taken up by the target cell, which may alter their function.…”

Section: Introductionmentioning

confidence: 99%

The Protein Corona as a Confounding Variable of Nanoparticle-Mediated Targeted Vaccine Delivery

et al. 2018

Self Cite

View full text Add to dashboard Cite

Nanocarriers (NC) are very promising tools for cancer immunotherapy. Whereas conventional vaccines are based on the administration of an antigen and an adjuvant in an independent fashion, nanovaccines can facilitate cell-specific co-delivery of antigen and adjuvant. Furthermore, nanovaccines can be decorated on their surface with molecules that facilitate target-specific antigen delivery to certain antigen-presenting cell types or tumor cells. However, the target cell-specific uptake of nanovaccines is highly dependent on the modifications of the nanocarrier itself. One of these is the formation of a protein corona around NC after in vivo administration, which may potently affect cell-specific targeting and uptake of the NC. Understanding the formation and composition of the protein corona is, therefore, of major importance for the use of nanocarriers in vaccine approaches. This Mini Review will give a short overview of potential non-specific interactions of NC with body fluids or cell surfaces that need to be considered for the design of NC vaccines for immunotherapy of cancer.

show abstract

Protein corona–mediated targeting of nanocarriers to B cells allows redirection of allergic immune responses

Abstract: Opsonization of lectin-coated NPs by activated complement components results in selective B-cell targeting. The intrinsic B-cell targeting property of lectin-coated NPs can be exploited for treatment of allergic immune responses.

Cited by 65 publications

References 41 publications

Lipid Nanoparticles for Cell-Specific <i>in Vivo</i> Targeted Delivery of Nucleic Acids

Lipid Nanoparticles for Cell-Specific <i>in Vivo</i> Targeted Delivery of Nucleic Acids

Exploiting the biomolecular corona: pre-coating of nanoparticles enables controlled cellular interactions

The Protein Corona as a Confounding Variable of Nanoparticle-Mediated Targeted Vaccine Delivery

Contact Info

Product

Resources

About